Synapse - Carol Portlock

Results (206)

Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma

Journal Article

Moskowitz, C. H.; Schoder, H.; Teruya-Feldstein, J.; Sima, C.; Iasonos, A.; Portlock, C. S.; Straus, D.; Noy, A.; Palomba, M. L.; O'Connor, O. A.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Prognostic value of quantitative image analysis (QIA) for determination of proliferative index in mantle cell lymphoma (MCL) treated with sequential chemotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR)

Meeting Abstract

Schaffel, R.; Hedvat, C.; Teruya-Feldstein, J.; Portlock, C. S.; Moskowitz, C. H.; Zelenetz, A. D.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Therapeutic and palliative benefit from single-agent irinotecan in multiply treated and highly refractory cases of lymphoma

Meeting Abstract

Caces, D. D.; Halaas, J.; Hamlin, P.; Noy, A.; Kewalramani, T.; Portlock, C. S.; Zelenetz, A. D.; O'Connor, O. A.; Gerecitano, J. F.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas

Meeting Abstract

Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
Blood (2009)

Fulltext@MSK | Save

Prognostic significance or positron emission tomography (FDG-PET) at baseline and after 4 cycles of R-CHOP in 75 patients with mantle cell lymphoma treated with intensive chemotherapy and autologous stem cell rescue

Meeting Abstract

Schaffel, R.; Moskowitz, C. H.; Maragulia, J. C.; Portlock, C. S.; Hedvat, C. V.; Zelenetz, A. D.
Blood (2009)

Fulltext@MSK | Save

Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant

Meeting Abstract

Moskowitz, A. J.; Hamlin, P. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M.; Meikle, J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Blood (2009)

Fulltext@MSK | Save

Classical Hodgkin's lymphoma

Book Section

Persky, D. O.; Portlock, C. S.
In Mushlin, S. B.; Greene, H. L. 2nd (Eds.) Decision Making in Medicine: An Algorithmic Approach. 3rd ed (2009)

Fulltext@MSK | Save

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Journal Article

O'Connor, O. A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C. H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; more...
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Pertussis Immunity and Response to Tetanus-Reduced Diphtheria-Reduced Pertussis Vaccine (Tdap) after Autologous Peripheral Blood Stem Cell Transplantation

Journal Article

Small, T. N.; Zelenetz, A. D.; Noy, A.; Rice, R. D.; Trippett, T. M.; Abrey, L.; Portlock, C. S.; Mccullagh, E. J.; Vanak, J. M.; Mulligan, A. M.; more...
Biology of Blood and Marrow Transplantation (2009)

Fulltext@MSK | Save

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial

Journal Article

O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
British Journal of Haematology (2009)

Fulltext@MSK | Save